Business
cbdMD Launches Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare
cbdMD, Inc. (NYSE American: YCBD), a leader in science-driven cannabinoid products, today announced the launch of its clinical healthcare channel, positioning the Company to support physicians, health systems, and value-based care organizations as federal policy establishes structured pathways for hemp-derived cannabinoid products within Medicare programs.
About this update from Cbdmd, Inc.
[{"type":"text","content":"Company brings one of the only combined clinical and toxicological safety dataset in the hemp-derived CBD category into a new provider channel as CMS activates cannabinoid access within value-based care models","length":209,"tagName":"p"},{"type":"text","content":"CHARLOTTE, N.C., April 1, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), a leader in science-driven cannabinoid products, today announced the launch of its clinical healthcare channel, positioning the Company to support physicians, health systems, and value-based care organizations as federal policy establishes structured pathways for hemp-derived cannabinoid products within Medicare programs.","length":405,"tagName":"p"},{"type":"image","alt":"cbdMD logo (PRNewsfoto/cbdMD, Inc.)","displaySize":"","headline":null,"caption":"cbdMD logo (PRNewsfoto/cbdMD, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":172,"url":"https://media.zenfs.com/en/prnewswire.com/39be855165955bdcbd347db26f31394c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1WsfRLZvEpvHr45sjmqUow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMwMw--/https://media.zenfs.com/en/prnewswire.com/39be855165955bdcbd347db26f31394c","width":400,"height":172}},"href":"https://mma.prnewswire.com/media/2829180/cbdMD_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"On March 20, 2026, the Centers for Medicare & Medicaid Services (CMS) published operational guidance activating the Substance Access Beneficiary Engagement Incentive (BEI), an existing incentive mechanism within CMS Innovation Center models, to include eligible hemp-derived cannabinoid products for the first time. Effective April 1, 2026, participating accountable care organizations and oncology practices in select models, including the Enhancing Oncology Model (EOM) and ACO REACH, may furnish eligible hemp-derived products to Medicare patients as part of physician-supervised care. The upcoming LEAD Model also incorporates the BEI framework when it is expected to launch on January 1, 2027. Together these models encompass thousands of physicians and millions of aligned Medicare beneficiaries.","length":806,"tagName":"p"},{"type":"text","content":"The BEI remains a limited, model-specific initiative, not a broad access or reimbursement program, and participating organizations independently...